The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Foundation Medicine; Guardant Health; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Bayer; Blueprint Medicines; Chugai Pharma; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - ARIAD (Inst); Daiichi Sankyo (Inst); Ignyta (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); TP Therapeutics (Inst)
Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).
 
Alice Tsang Shaw
No Relationships to Disclose
 
Jean-Francois Martini
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Inivata (Inst); Lilly (Inst); Novartis (Inst); Onxeo (Inst); ose pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer; Pfizer (Inst)
Speakers' Bureau - Bayer
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Peleton (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Pharmacyclics; Sysmex
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Novartis
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Lilly; Novartis
 
Ross A. Soo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Takeda; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Celgene; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Takeda; Yuhan
Research Funding - AstraZeneca
 
Gregory J. Riely
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Merck; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Foundation Medicine; Ignyta; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Ignyta (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Antonello Abbattista
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Francesca Toffalorio
No Relationships to Disclose
 
Holger C. Thurm
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Miyako Satouchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Ignyta (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
D. Ross Camidge
Honoraria - AstraZeneca; bio-thera; Daiichi Sankyo; G1 therapeutics; Genoptix; Hansoh; Ignyta; Lycera; Mersana; Revolution Medicines; Roche; takeda
Research Funding - Takeda
 
Steven Chuan-Hao Kao
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche
 
Rita Chiari
No Relationships to Disclose
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer; Takeda
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - EMD Serono (Inst); Merck (Inst)
 
Benjamin J. Solomon
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb (Inst); Eisai; Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Veristrat (Biodesix); UpToDate
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck; Novartis; Roche